Introduction: This study was performed to evaluate the degree of 3-day chemotherapy-induced nausea and vomiting (CINV) in children with cancer who received highly emetogenic chemotherapy (HEC) to ascertain the efficacy Metal Garden Stake of aprepitant single-dose on dayL 1 plus granisetron and dexamethasone (DEX).Methods: This clinical trial study was conducted on 120 patients in the age range of 5 to 18 years old who received chemotherapy.Patients were divided into two groups; Group A received aprepitant at 125 mg/kg on day 1 orally, followed by 80 mg/kg daily on days 2 and 3 and Group B received a single dose of aprepitant 125 mg/kg on day 1 orally and placebo on days 2 and 3.All groups received granisetron 3 mg/m2 on day 1 and DEX on days 1 to 3.
The primary and secondary endpoints were to evaluate the proportion of patients with acute, delayed and overall CINV within each group.Results: There were no significant differences between the two groups for vomiting, nausea or the use of rescue therapy.The number of patients without vomiting on day 1 was similar in both groups (96.5% CALENDULA CREAM BATH vs.
98.3%, respectively; p = 0.848).Conclusion: According to the results of this study, a single dose of aprepitant 125 mg/kg was as effective as administering three doses of aprepitant on 3 days.
Therefore, the use of a single dose of aprepitant in combination with other standard treatment regimens to prevent CINV in children who received HEC was safe and efficacious and can be beneficial.